We are live on
!
Find out more
Armistice Capital Portfolio holdings
AUM
$8.17B
Turnover
62.5%
1-Year Est. Return
68.82%
This Fund
S&P 500
This Quarter
Est. Return
-5.86%
1 Year Est. Return
+68.82%
3 Year Est. Return
+79.68%
5 Year Est. Return
+64.24%
10 Year Est. Return
+259.8%
AUM
$5.62B
AUM Growth
-$2.78B
(-33%)
Cap. Flow
-$739M
Cap. Flow
% of AUM
-13.15%
Top 10 Holdings %
Top 10 Hldgs %
56.27%
Holding
465
New
101
Increased
59
Reduced
84
Closed
204
Avg Time Held Equity + Options
1.1
years
Top 10 Avg Time Held Equity + Options
2
years
Top 20 Avg Time Held Equity + Options
1.6
years
Avg Time Held Equity only
1.1
years
Top 10 Avg Time Held Equity only
1.8
years
Top 20 Avg Time Held Equity only
1.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$44.1M |
| 2 |
Harmony Biosciences
HRMY
|
+$36.9M |
| 3 |
Travere Therapeutics
TVTX
|
+$33.9M |
| 4 |
Medline Inc
MDLN
|
+$22.4M |
| 5 |
Meta Platforms (Facebook)
META
|
+$20.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Kenvue
KVUE
|
+$70.6M |
| 2 |
Immunovant
IMVT
|
+$56.5M |
| 3 |
Dentsply Sirona
XRAY
|
+$53.6M |
| 4 |
GE HealthCare
GEHC
|
+$53.1M |
| 5 |
PTC Therapeutics
PTCT
|
+$51.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 46.19% |
| 2 | Healthcare | 38.27% |
| 3 | Technology | 7.29% |
| 4 | Consumer Discretionary | 4.25% |
| 5 | Communication Services | 1.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$814B
| $1.37B | 24.28% |
2,100,000
-900,000
| -30% | -$612M |
2022 Q3
14 quarters
|
|
2
PUT
iShares Russell 2000 ETF
IWM
$77.3B
| $868M | 15.43% |
3,500,000
-4,600,000
| -57% | -$1.19B |
2022 Q3
14 quarters
|
|
|
3
Travere Therapeutics
TVTX
$4.84B
| $146M | 2.59% |
4,897,417
+1,133,526
| +30% | +$33.9M |
2021 Q1
20 quarters
|
|
|
4
PTC Therapeutics
PTCT
$5B
| $141M | 2.51% |
2,074,449
-727,420
| -26% | -$51.5M |
2019 Q3
26 quarters
|
|
5
Madrigal Pharmaceuticals
MDGL
$10.6B
| $139M | 2.46% |
264,583
-1,122
| -0.4% | -$536K |
2019 Q1
28 quarters
|
|
6
CALL
Cytokinetics
CYTK
$8.69B
| $112M | 1.99% |
1,700,000
+200,000
| +13% | +$12.7M |
2024 Q1
8 quarters
|
|
7
CALL
Agios Pharmaceuticals
AGIO
$1.91B
| $108M | 1.93% |
3,200,000
+200,000
| +7% | +$5.67M |
2025 Q3
2 quarters
|
|
8
Supernus Pharmaceuticals
SUPN
$2.27B
| $98M | 1.74% |
1,895,347
-868,653
| -31% | -$44.2M |
2019 Q4
25 quarters
|
|
9
Neurocrine Biosciences
NBIX
$14B
| $95.4M | 1.7% |
724,000
-96,240
| -12% | -$12.8M |
2022 Q1
16 quarters
|
|
|
10
Agios Pharmaceuticals
AGIO
$1.91B
| $91.9M | 1.63% |
2,716,000
-320,000
| -11% | -$9.07M |
2022 Q3
14 quarters
|
|
|
11
Immunovant
IMVT
$5.56B
| $88.6M | 1.57% |
3,564,916
-2,182,239
| -38% | -$56.5M |
2023 Q3
10 quarters
|
|
12
Freshpet
FRPT
$3.27B
| $64.5M | 1.15% |
1,093,307
-202,693
| -16% | -$14.2M |
2025 Q1
4 quarters
|
|
13
Incyte
INCY
$22.9B
| $61.8M | 1.1% |
656,817
-441,285
| -40% | -$44M |
2019 Q2
27 quarters
|
|
14
Dyne Therapeutics
DYN
$2.79B
| $57.6M | 1.02% |
3,175,110
-74,598
| -2% | -$1.29M |
2023 Q2
11 quarters
|
|
15
Amazon
AMZN
$2.73T
| $54.6M | 0.97% |
262,137
-105,496
| -29% | -$23.2M |
2022 Q2
15 quarters
|
|
16
Ironwood Pharmaceuticals
IRWD
$595M
| $52.7M | 0.94% |
15,028,000
-997,000
| -6% | -$4.09M |
2023 Q3
10 quarters
|
|
|
17
Cytokinetics
CYTK
$8.69B
| $50.4M | 0.9% |
764,538
-228,228
| -23% | -$14.5M |
2024 Q1
8 quarters
|
|
|
18
CALL
Immunovant
IMVT
$5.56B
| $47.2M | 0.84% |
1,900,000
+1,150,000
| +153% | +$29.8M |
2025 Q4
1 quarter
|
|
|
19
Harmony Biosciences
HRMY
$2.23B
| $45.5M | 0.81% |
1,624,000
+1,124,000
| +225% | +$36.9M |
2025 Q4
1 quarter
|
|
20
Thermo Fisher Scientific
TMO
$256B
| $45M | 0.8% |
91,491
+28,653
| +46% | +$15.5M |
2025 Q2
3 quarters
|
|
21
Nektar Therapeutics
NKTR
$1.26B
| $41.6M | 0.74% |
578,000
-18,000
| -3% | -$1.02M |
2024 Q2
7 quarters
|
|
|
22
UnitedHealth
UNH
$358B
| $40M | 0.71% |
+148,000
| New | +$44.1M |
2026 Q1
0 quarters
|
|
23
Uber
UBER
$145B
| $37.3M | 0.66% |
518,760
+236,026
| +83% | +$18.2M |
2020 Q1
24 quarters
|
|
24
Immunocore
IMCR
$1.49B
| $35.8M | 0.64% |
1,188,000
+90,000
| +8% | +$2.91M |
2022 Q1
16 quarters
|
|
|
25
Dentsply Sirona
XRAY
$1.76B
| $34.8M | 0.62% |
3,000,000
-4,298,000
| -59% | -$53.6M |
2022 Q4
13 quarters
|
|
Similar funds
Armistice Capital's Q1 2026 Portfolio in Review
As of Q1 2026, Armistice Capital held 465 positions worth $5.62B, down 33% from $8.4B the previous quarter. Its ten largest holdings account for 56% of the portfolio.
Armistice Capital withdrew a net $739M in Q1 2026, closing 204 positions and reducing 84 holdings. Its most notable exit was argenx, an estimated $48.8M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 46% of assets, down from 51% a quarter earlier, followed by Healthcare and Technology.
Against the trend, Armistice Capital opened a new position in UnitedHealth worth $40M.
- Armistice Capital's largest Q1 2026 buy was UnitedHealth: 148,000 shares worth $40M.
- Armistice Capital added most to Harmony Biosciences in Q1 2026, an estimated $36.9M increase.
- Armistice Capital's biggest Q1 2026 reduction was Kenvue, cutting an estimated $70.6M.
- Armistice Capital fully exited argenx in Q1 2026, selling an estimated $48.8M.
- Armistice Capital's ten largest holdings make up 56% of its $5.62B portfolio in Q1 2026.
- Armistice Capital opened 101 new positions and closed 204 in Q1 2026.
- Armistice Capital's portfolio value fell 33% quarter-over-quarter to $5.62B.
Based on Armistice Capital's 13F filing for Q1 2026, filed 15 May 2026.